BIMI International Medical Inc. (BIMI) Cash Flow Statement
Where BIMI’s cash came from and went, 2023
December 31, 2023 · U.S. dollars- Cash from operations
- −$2.9M
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$3.5M −27.7% margin
- Returned to shareholders
- —
- Change in cash
- −$6,208 cash at year-end $611,031
Cash from operations
−$2.9M
Investments (net)
−$960,758
Shares issued
+$6.6M
Other financing
−$3.5M
Currency & other
+$716,786
Change in cash
−$6,208
Drawn to scale: where the cash came from and how it was used. Hover for values.
BIMI operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
BIMI cash flow trends, 2014–2023
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$995,0802014 | −$2.9M2023 | — | |
| Capital expenditures | $341,6342014 | $02023 | −100.0% | |
| Free cash flow | −$1.3M2014 | −$3.5M2023 | — | |
| Free cash flow margin | −13.4%2014 | −27.7%2023 | −14.3 pts | |
| Stock-based compensation | $94,0522014 | $355,2002017 | +55.7%/yr | |
| Share buybacks (net) | $02017 | $02019 | — | |
| Capex / revenue | 3.4%2014 | 0.0%2023 | −3.4 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BIMI cash flow by activity
OperatingInvestingFinancingChange in cash
BIMI net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BIMI cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$10.5M | −$22.4M | −$34.9M | −$3.8M | −$2.3M | −$16.8M | −$1.6M | −$1.8M | −$969,442 | −$617,291 |
| Depreciation & amortization | $248,702 | $223,560 | $244,116 | $56,041 | $261,983 | $1.0M | $944,012 | $998,189 | $1.3M | $844,657 |
| Stock-based compensation | — | — | — | — | — | — | $355,200 | $96,000 | — | $94,052 |
| Change in working capital | −$491,227 | $2.4M | $6.7M | −$2.9M | $164,855 | −$15.1M | −$666,519 | $883,222 | −$3.2M | −$1.7M |
| Other non-cash items | $7.9M | $9.6M | $26.7M | $3.1M | −$222,630 | $30.5M | $37,493 | $0 | $442,858 | $355,343 |
| Cash from operating activities | −$2.9M | −$10.3M | −$1.3M | −$3.5M | −$2.1M | −$343,970 | −$908,229 | $159,832 | −$2.5M | −$995,080 |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | −$814,684 | −$258,961 | −$258,961 | −$258,961 | −$258,961 | −$407,505 | −$663,271 | −$341,634 |
| Investments (net) | −$960,758 | −$536,866 | −$696,517 | −$724,465 | $166,717 | — | $0 | −$407,505 | — | — |
| Acquisitions & other investing | — | $0 | $814,684 | $258,961 | $258,961 | $425,678 | $425,678 | $407,505 | $2.3M | $0 |
| Cash from investing activities | — | −$536,866 | −$696,517 | −$724,465 | $166,717 | $166,717 | $166,717 | −$407,505 | $1.6M | −$341,634 |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | — | — | $3.1M | $500,000 | $16,503 | — | — | — |
| Net borrowing (repayment) | — | −$436,560 | $6.6M | $3.8M | $1.0M | −$1.1M | $1.0M | −$45,160 | $48,251 | $1.6M |
| Shares issued | $6.6M | $5.0M | $0 | $0 | $0 | $500,000 | $0 | $0 | $0 | $0 |
| Other financing | −$3.5M | $3.9M | $259,161 | $148,700 | −$2.3M | $269,522 | $0 | $0 | $0 | $0 |
| Cash from financing activities | $3.1M | $8.4M | $6.9M | $4.0M | $1.8M | $211,264 | $1.1M | −$45,160 | $48,251 | $1.6M |
| Summary | ||||||||||
| Net change in cash | −$6,208 | −$2.3M | $4.7M | $133,708 | $36,674 | −$84,798 | $157,517 | −$309,934 | −$869,559 | $283,370 |
| Cash at end of period | $611,031 | $2.3M | $4.8M | $135,309 | $36,674 | $197,356 | $282,154 | $124,637 | $434,571 | $1.3M |
| Free cash flow | −$3.5M | −$10.3M | −$2.1M | −$3.8M | −$2.1M | −$343,970 | −$908,229 | −$247,673 | −$3.1M | −$1.3M |
| Free cash flow margin | −27.7% | −86.7% | −9.8% | −29.4% | −1,307.0% | −5.3% | −10.7% | −4.1% | −46.7% | −13.4% |
| Capex / revenue | 0.0% | 0.0% | 3.8% | 2.0% | 163.9% | 4.0% | 3.0% | 6.7% | 9.9% | 3.4% |
| Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | Jun '21 | Mar '21 | Dec '20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$3.0M | $1.1M | −$883,764 | −$11.8M | −$3.7M | −$6.3M | −$2.7M | −$29.7M | −$1.7M | −$275,738 | −$3.3M | −$4.4M |
| Depreciation & amortization | −$17,361 | $74,813 | $53,800 | $58,319 | $39,461 | $36,622 | $89,159 | $64,911 | $60,345 | $82,844 | $35,958 | −$754,223 |
| Stock-based compensation | $0 | — | — | — | $829,963 | $0 | −$585,000 | — | — | — | $585,000 | −$1 |
| Change in working capital | −$1.6M | −$5.1M | $5.0M | $356,060 | −$4.6M | $6.3M | −$53,258 | $6.3M | $2.9M | −$1.8M | −$658,574 | −$2.6M |
| Other non-cash items | $3.2M | $3.4M | −$1.3M | $8.5M | −$829,952 | $1.7M | $1.1M | $24.6M | −$163,527 | $167,351 | $1.6M | $7.0M |
| Cash from operating activities | −$1.5M | −$570,375 | $2.8M | −$2.9M | −$8.3M | $1.7M | −$2.2M | $1.3M | $1.0M | −$1.9M | −$1.7M | −$702,539 |
| Investing activities | ||||||||||||
| Capital expenditures | −$603,892 | $0 | −$3 | $0 | $0 | $0 | −$989,852 | −$989,852 | −$1.4M | −$339,135 | −$36,100 | −$137,785 |
| Investments (net) | — | — | $0 | −$356,866 | −$180,000 | $0 | $0 | $1.1M | −$1.5M | −$326,807 | $39,105 | −$11.1M |
| Acquisitions & other investing | $0 | — | −$356,863 | — | $0 | −$1.7M | $2.7M | $989,852 | $1.4M | $339,135 | $36,100 | $137,785 |
| Cash from investing activities | −$603,892 | — | −$356,866 | — | −$180,000 | −$1.7M | $1.7M | $1.1M | −$1.5M | −$326,807 | $39,105 | −$11.1M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | — | — | — | $2,000 | — |
| Net borrowing (repayment) | — | — | −$86,427 | −$86,427 | −$242,745 | −$199,681 | −$199,393 | $2.1M | $259,290 | $27,712 | $162,950 | $4.2M |
| Shares issued | $1.6M | $0 | $0 | $5.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$567,246 | $330,230 | −$2.1M | −$838,158 | $4.9M | $5.4M | −$379,105 | −$478,183 | $0 | −$164,067 | $4.2M | −$3.8M |
| Cash from financing activities | $1.0M | $330,230 | −$2.2M | $4.1M | $4.7M | $5.2M | −$578,498 | $1.6M | $259,290 | −$136,355 | $4.4M | $444,503 |
| Summary | ||||||||||||
| Net change in cash | −$937,613 | $201,681 | −$606,573 | $1.5M | −$4.0M | $3.5M | −$3.2M | $4.6M | −$416,770 | −$2.2M | $2.7M | −$11.5M |
| Cash at end of period | $994,131 | $1.9M | $1.7M | $2.3M | $1.0M | $4.7M | $1.6M | $4.8M | $214,444 | $631,214 | $2.8M | $135,309 |
| Free cash flow | −$2.1M | −$570,375 | $2.8M | −$2.9M | −$8.3M | $1.7M | −$2.2M | $2.3M | −$387,777 | −$2.2M | −$1.8M | −$840,324 |
| Free cash flow margin | −82.4% | −10.3% | 88.1% | — | −113.3% | 61.4% | −42.8% | 120.5% | −2.8% | −23.8% | −81.4% | −15.2% |
| Capex / revenue | 23.8% | 0.0% | 0.0% | — | 0.0% | 0.0% | 19.7% | 52.7% | 10.4% | 3.7% | 1.7% | 2.5% |
| Operating cash flow / net income | — | −0.54 | — | — | — | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BIMI cash generation
In fiscal 2023 (ended December 31, 2023), BIMI International Medical generated -$2.9 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$3.5 million, −27.7% of revenue. Cash and equivalents fell by $0.0 million over the year.
Related: BIMI income statement, BIMI balance sheet. See the BIMI stock overview for the latest quote and news.
BIMI cash flow FAQ
What is BIMI International Medical's free cash flow?
BIMI International Medical's free cash flow was -$3.5 million in fiscal 2023: -$2.9 million of operating cash flow minus $0 of capital expenditures It was -$10.3 million a year earlier..
How much cash does BIMI International Medical generate from operations?
BIMI International Medical generated -$2.9 million of cash from operating activities in fiscal 2023.